Female Contraception Clinical Trial
Official title:
Prospective Phase III Multi-center Open-label Study of the Efficacy, Safety, and Acceptability of Mifepristone 50 mg Once-weekly as a Contraceptive
Participants in the study will use mifepristone 50 mg once-a-week for one year as a contraceptive. With this, we want to confirm that the chances of getting pregnant while using this contraceptive are very small. We also want to demonstrate that the use of mifepristone is safe, and it does not lead to any severe health problems. We expect fewer side effects compared to other frequently used contraceptives with hormones. Mifepristone does not contain these hormones. It is important to know how people experience that use of one tablet a week.
Mifepristone 50 mg, a progesterone receptor modulator, is a proven safe emergency contraceptive and a promising new weekly contraceptive. As mifepristone does not contain estrogens or progestogens, we anticipate users will not experience the undesirable side effects and health risks of current hormonal contraceptives. Furthermore, pills are a highly desired formulation approach and a weekly regimen instead of daily administration will likely contribute to a high acceptability and adherence among users. Based on promising early stage clinical data, we expect the use of weekly mifepristone 50 mg as a contraceptive will be safe, effective, and acceptable. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00653016 -
An Open-label, Multicentre Study on Preference and Satisfaction of Canadian Women for the Transdermal Contraceptive Patch vs. Previous Primary Contraceptive Method
|
Phase 4 | |
| Completed |
NCT00511784 -
Relative Risks for Non-fatal Venous Thromboembolism, Ischemic Stroke and Myocardial Infarction in Users of ORTHO EVRA(Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared to Levonorgestrel-containing Oral Contraceptives.
|
N/A | |
| Completed |
NCT00236769 -
A Study of Efficacy and Safety With the Transdermal Contraceptive System.
|
Phase 3 | |
| Active, not recruiting |
NCT03124160 -
Compare Two Copper IUDs: Mona Lisa NT Cu380 Mini and ParaGard
|
Phase 3 | |
| Completed |
NCT00709189 -
Bioequivalence Study of the Oral Contraceptive Tablet Containing Norgestimate (NGM)/Ethinyl Estradiol (EE) With or Without Folic Acid in Healthy Women.
|
Phase 1 | |
| Completed |
NCT00258063 -
A Study to Evaluate the Exposure of Norelgestromin and Ethinyl Estradiol From Commercial Lots of EVRA (a Transdermal Contraceptive Patch Manufactured by LOHMANN Therapie-Systeme) and CILEST (an Oral Contraceptive)
|
Phase 1 | |
| Completed |
NCT00775086 -
Bioequivalence Study of Patches With Different Equilibration Profiles
|
Phase 1 | |
| Recruiting |
NCT04143659 -
A Study to Evaluate the PK and PD of IM or SQ Injections of Levonorgestrel Butanoate (LB) for Female Contraception
|
Phase 1 | |
| Completed |
NCT00697307 -
Bioequivalence Study of Patches With Different Release Profiles
|
N/A | |
| Completed |
NCT00261482 -
Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.
|
Phase 4 | |
| Completed |
NCT01286948 -
Prevention of Ovulation Achieved by Single Intra-vaginal Administration of Levogel as Compared to Oral LNG
|
Phase 1 | |
| Completed |
NCT00236795 -
A Study of Efficacy and Safety With the Transdermal Contraceptive System Versus Triphasil.
|
Phase 3 | |
| Completed |
NCT01833793 -
Descriptive, Prospective, Non-interventional Study (NIS) to Describe Mirena and Amenorrhea Related Acceptability in Contraception Indication in Medical Practice
|
N/A | |
| Recruiting |
NCT02257671 -
Oral Contraceptives and Economic Behaviour
|
N/A | |
| Recruiting |
NCT03432416 -
Study of Efficacy, Cycle Control, and Safety of a NES-E2 Contraceptive Vaginal Ring
|
Phase 2 | |
| Completed |
NCT01178125 -
A Study to Evaluate the Efficacy and Safety of DR-102 for the Prevention of Pregnancy
|
Phase 3 | |
| Completed |
NCT00254865 -
A Comparative Pharmacokinetic Study of ORTHO EVRA (a Transdermal Contraceptive Patch) and CILEST (an Oral Contraceptive) in Healthy Female Volunteers
|
Phase 1 | |
| Completed |
NCT00258076 -
A Study to Evaluate the Hormone Exposure From Multiple Commercial Lots of ORTHO EVRA (a Transdermal Contraceptive Patch)
|
Phase 1 | |
| Completed |
NCT00377988 -
A Postmarketing Study of the Risk of Venous Thromboembolism (Blood Clots), Myocardial Infarction (Heart Attacks), and Stroke Among Women Using ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) Compared With Women Who Take Oral Contraceptives for Birth Control
|
N/A | |
| Completed |
NCT00331071 -
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
|
N/A |